E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 18, 2014, Pages 6834-6839

  Samant, Rahul S ^a   Clarke, Paul A ^a   Workman, Paul ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRAF; ERBB2; Oncoprotein; Protein degradation; Protein quality control

Indexed keywords

CULLIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; NEDD8 PROTEIN; SMALL INTERFERING RNA; TANESPIMYCIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; COMPLEX FORMATION; CONJUGATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; UBIQUITINATION;

BRAF; ERBB2; ONCOPROTEIN; PROTEIN DEGRADATION; PROTEIN QUALITY CONTROL;

BENZOQUINONES; CELL LINE, TUMOR; COLONIC NEOPLASMS; CULLIN PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HT29 CELLS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASMS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; TRANSLATIONAL MEDICAL RESEARCH; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 84899837467     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322412111     Document Type: Article

References (36)

1. Taipale M, et al. (2012) Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell 150(5):987-1001.
2. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2(1):3-24.
3. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: Are we there yet Clin Cancer Res 18(1):64-76.
4. Panaretou B, et al. (1998) ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 17(16):4829-4836.
5. Pea rl LH, Prodromou C (2006) Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 75:271-294.
6. Schulte TW, An WG, Neckers LM (1997) Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 239(3):655-659.
7. Whitesell L, Cook P (1996) Stable and specific binding of heat shock protein by gelda namycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10(6):705-712.
8. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N (1995) Herbimycin A induces th e 20 S proteasome-and ubiquitin-dependent degradation of receptor tyrosine kinases. J Biol Chem 270(28):16580-16587.
9. Connell P, et al. (2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3(1):93-96.
10. Xu W, et al. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99(20):12847-12852.
11. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA (2001) Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanam ycin results in cytostasis and apoptosis. Cancer Res 61(10):4003-4009.
12. Ehrlich ES, et al. (2009) Reg ulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA 106(48):20330-20335.
13. Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6(1):9-20.
14. Zimmerman ES, Schulman BA, Zheng N (2010) Structural assembly of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol 20(6):714-721.
15. Eccles SA, et al. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68(8): 2850-2860.
16. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298(5600):1912-1934.
17. da Rocha Dias S, et al. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65(23):10686-10691.
18. Grbovic OM, et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103(1):57-62.
19. Basso AD, Solit DB, Munster PN, Rosen N (2002) Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21(8):1159-1166.
20. Dikic I, Robertson M (2012) Ubiquitin ligases and beyond. BMC Biol 10:22.
21. Tikhomirov O, Carpenter G (2000) Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation. J Biol Chem 275(34):26625-26631.
22. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B (2006) Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 119(Pt 1): 85-95.
23. Smith JR, Clarke PA, de Billy E, Workman P (2009) Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28(2):157-169.
24. Holmes JL, Sharp SY, Hobbs S, Workman P (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res 68(4): 1188-1197.
25. Pan ZQ, Kentsis A, Dias DC, Yamoah K, Wu K (2004) Nedd8 on cullin: Building an expressway to protein destruction. Oncogene 23(11):1985-1997.
26. Kelsall IR, et al. (2013) TRIAD1 and HHARI bind to and are activated by distinct neddylated Cullin-RING ligase complexes. EMBO J 32(21):2848-2860.
27. Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302(5647):1056-1060.
28. Lundgren K, et al. (2009) BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 8(4):921-929.
29. Brough PA, et al. (2008) 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J Med Chem 51(2):196-218.
30. Byrd PJ, et al. (1997) Identification and analysis of expression of human VACM-1, a cullin gene family member located on chromosome 11q22-23. Genome Res 7(1):71-75.
31. Carter SL, et al. (1994) Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res 54(23):6270-6274.
32. Van Dort C, et al. (2003) VACM-1, a cul-5 gene, inhibits cellular growth by a mechanism that involves MAPK and p53 signaling pathways. Am J Physiol Cell Physiol 285(6): C1386-C1396.
33. Burnatowska-Hledin MA, et a l. (2004) T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene. Biochem Biophys Res Commun 319(3):817-825.
34. Fay MJ, et al. (2003) Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues. Mol Cancer 2:40.
35. Jhaveri K, Taldone T, Modi S, Chiosis G (2012) Advances in the clinical development of heat shock protein (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823(3): 742-755.
36. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998) In vit ro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77(3):366-373.